Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week High – What’s Next?

Posted by Geri Gentry on Aug 13th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) shares hit a new 52-week high on Tuesday . The company traded as high as $27.13 and last traded at $26.8390, with a volume of 92718 shares trading hands. The stock had previously closed at $26.50.

Analysts Set New Price Targets

DYN has been the subject of a number of research analyst reports. Morgan Stanley dropped their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, July 31st. TD Cowen initiated coverage on Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating for the company. Royal Bank Of Canada upped their price target on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating on the stock. Finally, Sanford C. Bernstein lifted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.42.

View Our Latest Analysis on DYN

Dyne Therapeutics Stock Down 2.0%

The firm’s 50-day moving average price is $22.51 and its 200-day moving average price is $19.39. The company has a market cap of $4.89 billion, a price-to-earnings ratio of -7.86 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Brian S. Posner bought 2,500 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $17.12 per share, for a total transaction of $42,800.00. Following the completion of the purchase, the director owned 18,000 shares in the company, valued at $308,160. This represents a 16.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the sale, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have purchased 9,000 shares of company stock valued at $156,800 and have sold 1,552,268 shares valued at $34,264,958. 9.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Several large investors have recently bought and sold shares of DYN. T. Rowe Price Investment Management Inc. lifted its position in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares in the last quarter. BlackRock Inc. acquired a new stake in Dyne Therapeutics during the 2nd quarter valued at $275,500,000. Orbis Allan Gray Ltd purchased a new stake in Dyne Therapeutics during the 4th quarter worth $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in Dyne Therapeutics during the 2nd quarter worth $30,378,000. Finally, Perceptive Advisors LLC lifted its holdings in Dyne Therapeutics by 543.7% in the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after buying an additional 2,938,500 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.